Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Market dynamics of Addison's disease become prevalent in the realm wherein the scarcely common endocrine disorder merges with the mutable constitution of health care system. The main one affecting the Addison's Disease market is the worldwide increased awareness and acknowledgement of this disease. The spread of medical awareness and the advancement of diagnostic techniques make more cases of Addison's disease detectable, which further heightens the demand for treatment. The rarity of Addison's Disease, which is a condition that arises when adrenal glands don’t produce enough hormones, is one of the defining qualities of this market, highlighting the need for personalized therapies.
Medical research and technology development act as a vital influence on Addison’s Disease market dynamics. Pharmaceutical companies invest in the development of new drug therapies targeting hormonal imbalances, such as glucocorticoid and mineralocorticoid replacement therapies. The appearance of new formulations, convenient dosages, and personalized treatment regimens promote the dynamic emergence of the market. Currently, studies are centered on the best version of hormonal replacement therapy and finding medications that can serve as disease modifying drugs for Addison's Disease.
Regulatory factors are determinant in molding the Addison's Disease market dynamics. Stern laws regulate the process of approving and commercializing medicines for rare diseases providing for their safety and efficiency. Compliance with regulatory standards is a core facet of pharmaceutical companies' new drug development, consequently affecting approval and market entry options. The regulatory landscape is not only a protective shield for patients but also ensures that early and late-stage innovations are in line with market demand in the Addison's Disease space.
Economic considerations create an important part of the accessibility and usage of Addison's Disease treatment solution. The economic burden related to chronic hormone replacement therapy involving the costs of medical care and the requirement for lifelong medications strongly impacts the choices made by patients and healthcare providers regarding the treatment plan. As regards the Addison's Disease medications, the affordability, insurance coverage, and reimbursement policies play a significant role in determining the availability and the frequency of their use in regions that have different healthcare setups. If we want market dynamics to be favorable and help millions of individuals suffering from Addison's disease access quality treatments, we need to tackle the economic factors.
A notable fact about Addison's disease market dynamics is the competitive situation among pharmaceutical companies. Enterprises try to achieve a competitive advantage by innovation of hormone replacement therapies, strategic collaboration and patient support. The fact that the market is niche calls for the work of pharmaceutical companies to partner with healthcare providers and patient advocacy groups to ensure the well-being of the individuals with Addison's Disease at their best.
Addison’s Disease Market Highlights:
Addison’s Disease Market Overview:
Addison’s Disease Market Size was valued at USD 2.21 Billion in 2023. The Addison’s Disease industry is projected to grow from USD 2.34 Billion in 2024 to USD 5.35 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.84% during the forecast period (2024 - 2032). Addison's disease is a condition in which the body generates insufficient levels of certain hormones made by the adrenal glands. The adrenal glands generate too little cortisol and typically insufficient quantities of aldosterone in people with Addison's disease.
Adrenal insufficiency is another name for it. Addison's disease may afflict people of all ages and impact both men and women. The market is predicted to rise due to reasons such as the rising prevalence of Addison's disease, increased awareness of the condition, and rising healthcare spending. Lack of knowledge and difficulty to detect the condition in its early stages, on the other hand, may limit market growth throughout the projection period.
Segmentation
The Global Addison’s Disease Market has been segmented into diagnosis, treatment and end user.
The market, on the basis of diagnosis, has been segmented into laboratory tests and imaging tests. Laboratory tests have been further segmented into blood tests, ACTH stimulation tests, insulin-induced hypoglycemia test, and other tests. Blood tests are expected to hold the largest market share owing to their high effectiveness to diagnose the disease and preference among the physicians. ACTH stimulation test is expected to be the fastest growing market due to the low cost of the diagnosis method. Imaging tests have been segmented into chest radiography and CT scan.
The market, by treatment, has been segmented into oral corticosteroids and corticosteroids injections.
The market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, and other end users.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Addison’s disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
- Pfizer Inc
- Boehringer Ingelheim International GmbH
- Shire
- Tocris Bioscience
- GlaxoSmithKline plc
- Merck KGaA
- Lupin Pharmaceuticals, Inc
- Abbott
- Amgen Limited & Amgen Ireland Limited
- Bayer AG
- Biogen
- Eli Lilly and Company
- Novartis AG
- Diurnal
- Switzer Life science Pvt. Ltd
Regional Market Summary
Global Addison’s Disease Market Share (%), by Region, 2017
Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports
Geographically, the Americas is anticipated to dominate the global Addison's disease market owing to a well-developed healthcare sector and the rising prevalence of the disease. According to a report published by the Centers Medicare and Medicaid Services in April 2018, National Healthcare Expenditure grew by 4.3% to USD 3.3 trillion in 2016 from the previous year.
Europe is expected to hold the second largest position in the global market. The market growth in this region is attributed to the increasing number of Addison’s disease cases and the developed healthcare infrastructure. According to the World Health Organization, Germany spent USD 5182 per capita on healthcare.
The Addison’s disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the increasing prevalence of Addison’s disease and growing awareness of the same. According to the World Bank Group, India spent 3.89% of its GDP on health in 2015.
The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.Recent Development
Lupin Ltd (Lupin) is a pharmaceutical company that produces and markets generic and branded pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Cardiovascular, diabetes etc are all part of the company's product range. Oral, ophthalmic, dermatological, and inhalation product research are key priorities for the organization. The company's operations are reported under a single segment, Pharmaceuticals. Formulations, active pharmaceutical ingredients (APIs), generic formulations, and biotechnology products are all part of Lupin's business.
In August 2015, Amgen, a biotechnology corporation located in the United States, launched its significantly enlarged production plant in Dun Laoghaire, Ireland. The $300 million expansion expanded manufacturing facilities to the existing factory, enhancing its capabilities and positioning it as a major hub for Amgen's global operations. The move was part of Amgen's long-term plan to manufacture all of its pharmaceuticals at the Dun Laoghaire facility, ensuring a steady supply of Amgen's medicines for severely sick patients across the world.
Global Addison’s Disease Market, by Diagnosis
- Laboratory Tests
- Blood Tests
- ACTH Stimulation Tests
- Insulin-Induced Hypoglycemia Test
- Other Tests
- Imaging Tests
- Chest Radiography
- CT Scan
Global Addison’s Disease Market, by Treatment
- Oral Corticosteroid
- Corticosteroid Injections
Global Addison’s Disease Market, by End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Other End Users
Global Addison’s Disease Market, by Region
- Americas
- North America
- US
- Canada
- South America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Global Addison’s Disease Market, by Key Players
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Shire
- Tocris Bioscience
- GlaxoSmithKline Plc
- Merck KGaA
- Lupin Pharmaceuticals, Inc.
- Abbott
- Amgen Limited & Amgen Ireland Limited
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
